TALS
Income statement / Annual
Last year (2024), Talaris Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Talaris Therapeutics, Inc.'s net income was -$73.21 M.
See Talaris Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$66.99 M
|
$57.01 M
|
$34.25 M
|
$15.28 M
|
$13.37 M
|
| General & Administrative Expenses |
$22.75 M
|
$19.47 M
|
$13.26 M
|
$7.41 M
|
$5.01 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$22.75 M
|
$19.47 M
|
$13.26 M
|
$7.41 M
|
$5.01 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$89.73 M
|
$76.48 M
|
$47.51 M
|
$22.68 M
|
$18.38 M
|
| Cost And Expenses |
$0.00
|
$76.48 M
|
$47.51 M
|
$22.68 M
|
$18.38 M
|
| Interest Income |
$0.00
|
$900.00
|
$0.00
|
$400.00
|
$200.00
|
| Interest Expense |
$0.00
|
$2.58 M
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$2.16 M
|
$623.00 K
|
$447.00 K
|
$379.00 K
|
| EBITDA |
-$89.73 M |
-$69.15 M |
-$47.54 M |
-$22.24 M |
-$18.00 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$16.52 M
|
$2.58 M
|
-$326.00 K
|
-$23.00 K
|
$223.00 K
|
| Income Before Tax |
-$73.21 M
|
-$73.89 M
|
-$47.83 M
|
-$22.71 M
|
-$18.16 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$223.00 K
|
| Net Income |
-$73.21 M
|
-$68.73 M
|
-$48.16 M
|
-$22.73 M
|
-$17.93 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.89 |
-16.66 |
-16.53 |
-34 |
-28.09 |
| EPS Diluted |
-2.89 |
-16.66 |
-16.53 |
-34 |
-28.09 |
| Weighted Average Shares Out |
$25.35 M
|
$4.12 M
|
$2.91 M
|
$668.51 K
|
$638.33 K
|
| Weighted Average Shares Out Diluted |
$25.35 M
|
$4.12 M
|
$2.91 M
|
$668.51 K
|
$638.33 K
|
| Link |
|
|
|
|
|
